Analystreport

Adamas Pharmaceuticals Inc (NASDAQ: ADMS) had its "sell" rating re-affirmed by analysts at Mizuho. They now have a $5.00 price target on the stock.

Adamas Pharmaceuticals, Inc.  (ADMS) 
Last adamas pharmaceuticals, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.adamaspharma.com/investors